Kiranmayi Chilappa, MD
Cardiovascular Disease · Kansas City, MONPI 1366551533
Payments from drug & device makers
Across 246 payments — averaging $22.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Amgen$470
- E.r. Squibb & Sons, L.L.C.$432
- Pfizer$380
- Sanofi-aventis U.S. LLC$347
- Novartis$316
- plus $2K from 24 others
What the payments were for
- Travel & lodging$1,03619%
- Food & beverage$4,28478%
- Education$1383%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 16 | $1,311 |
| Amgen | 30 | $470 |
| E.r. Squibb & Sons, L.L.C. | 25 | $432 |
| Pfizer | 22 | $380 |
| Sanofi-aventis U.S. LLC | 21 | $347 |
| Novartis | 20 | $316 |
| Boston Scientific | 15 | $303 |
| Johnson & Johnson | 15 | $243 |
| Merck | 15 | $234 |
| AstraZeneca | 13 | $218 |
| Lantheus Medical Imaging, Inc. | 8 | $188 |
| Novo Nordisk | 7 | $144 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $127 |
| Angiodynamics, Inc. | 1 | $104 |
| Astellas Pharma US Inc | 2 | $101 |
| Boehringer Ingelheim | 5 | $88 |
| Bayer | 3 | $70 |
| Irhythm Technologies, Inc. | 3 | $63 |
| Alnylam Pharmaceuticals Inc. | 3 | $49 |
| Philips North America LLC | 3 | $48 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $45 |
| Actelion Pharmaceuticals US, Inc. | 2 | $27 |
| Sanofi | 1 | $26 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Blue Earth Diagnostics | 1 | $21 |
| Amryt Pharma Holdings Ltd | 1 | $18 |
| Medtronic | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Regeneron Healthcare Solutions, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRICLIP$153
How this compares
$5,458 in reported general payments places this provider in the 65th percentile of 391 cardiovascular disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 90 | $114,087 |
| EntrestoSacubitril/Valsartan | 66 | $73,897 |
| XareltoRivaroxaban | 41 | $49,532 |
| JardianceEmpagliflozin | 21 | $35,591 |
| Metoprolol Succinate | 242 | $2,650 |
| Atorvastatin Calcium | 254 | $2,281 |
| Carvedilol | 268 | $2,077 |
| Losartan Potassium | 279 | $2,059 |
| Rosuvastatin Calcium | 173 | $1,873 |
| Torsemide | 49 | $1,585 |
| Potassium Chloride | 62 | $1,207 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 52 | $1,100 |
| Hydralazine Hcl | 35 | $928 |
| ClopidogrelClopidogrel Bisulfate | 62 | $882 |
| Colchicine | 11 | $816 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $380 | $114,08790 claims |
| NovartisEntresto | $316 | $73,89766 claims |
| Johnson & JohnsonXarelto | $243 | $49,53241 claims |
| Boehringer IngelheimJardiance | $88 | $35,59121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 391 cardiovascular disease providers in Missouri.
Other cardiovascular disease in Kansas City
- Mikhail KosiborodKansas City$27.8M
- John SpertusKansas City$2.3M
- Rajat BaruaKansas City$264K
- Kyle LehenbauerKansas City$108K
- Paramdeep BawejaKansas City$68K
- Deepa UpadhyayaKansas City$58K
- John LeeKansas City$45K
- David SkolnickKansas City$44K
- Garth GrahamKansas City$32K
- Mohammad TahirSaint Louis$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.